TMO Stock Analysis: Thermo Fisher Scientific | NYSE
Diagnostics & Research | NYSE, USA | Market Cap: 194.522m USD | 12M Return: 22.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.03B
EPS Trend: 92.1%
Qual. Beats: 3
Rev. Trend: 58.2%
Qual. Beats: 5
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Thermo Fisher Scientific Inc. (TMO) is a global supplier to the life sciences and healthcare industries, operating four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. Its offerings span reagents, instruments, consumables, clinical diagnostics (including allergy/autoimmune testing, microbiology, and transplant diagnostics), and outsourced services for pharmaceutical and clinical research customers in North America, Europe, and Asia-Pacific. The company was founded in 1956, is headquartered in Waltham, Massachusetts, and has been publicly listed since 1978.
The company sits within the Health Care sector, specifically the Life Sciences Tools & Services sub-industry, and functions largely as a diversified instrument-and-consumables vendor with a growing biopharma services franchise. Its business model combines recurring consumables and reagents revenue with higher-margin analytical instruments, supported by pharma services that address drug development and bioprocessing needs across academic, government, and industrial customers.
- Biopharma services revenue grows on clinical trial demand and pharma R&D budgets
- China biosecure legislation threatens life sciences demand exposure
- PPD integration and cost programs expand operating margins
| Net Income: 6.86b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.83 > 1.0 |
| NWC/Revenue: 17.03% < 20% (prev 23.79%; Δ -6.76% < -1%) |
| CFO/TA 0.07 > 3% & CFO 8.29b > Net Income 6.86b |
| Net Debt (39.9b) to EBITDA (11.2b): 3.58 < 3 |
| Current Ratio: 1.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (373.0m) vs 12m ago -1.58% < -2% |
| Gross Margin: 39.41% > 18% (prev 40.56%; Δ -1.15% > 0.5%) |
| Asset Turnover: 42.57% > 50% (prev 43.31%; Δ -0.74% > 0%) |
| Interest Coverage Ratio: 5.89 > 6 (EBIT TTM 8.66b / Interest Expense TTM 1.47b) |
| A: 0.07 (Total Current Assets 22.3b - Total Current Liabilities 14.6b) / Total Assets 113b |
| B: 0.54 (Retained Earnings 60.6b / Total Assets 113b) |
| C: 0.08 (EBIT TTM 8.66b / Avg Total Assets 106b) |
| D: 0.85 (Book Value of Equity 51.9b / Total Liabilities 61.3b) |
| Altman-Z'' = 3.63 = AA |
| DSRI: 1.05 (Receivables 10.9b/9.82b, Revenue 45.2b/42.9b) |
| GMI: 1.03 (GM 40.56% / 39.41%) |
| AQI: 1.06 (AQ_t 0.71 / AQ_t-1 0.67) |
| SGI: 1.05 (Revenue 45.2b / 42.9b) |
| TATA: -0.01 (NI 6.86b - CFO 8.29b) / TA 113b) |
| Beneish M = -2.88 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 527.05 with a total of 1,232,959 shares traded. Over the past week, the price has changed by +0.69%, over one month by +9.45%, over three months by +6.34% and over the past year by +22.81%.
Current recommended Stop Loss: 508.50 (which is 3.5% or 1.2 ATR below the current price).
Thermo Fisher Scientific has received a consensus analysts rating of 4.39. Therefore, it is recommended to buy TMO.
- StrongBuy: 18
- Buy: 7
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 596.3 | 13.1% |
P/E Trailing = 28.7289
P/E Forward = 21.0526
P/S = 4.3039
P/B = 3.7456
P/EG = 1.7259
Revenue TTM = 45.2b USD
EBIT TTM = 8.66b USD
EBITDA TTM = 11.2b USD
Long Term Debt = 40.1b USD (from longTermDebt, last quarter)
Short Term Debt = 3.09b USD (from shortTermDebt, last quarter)
Debt = 43.2b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 39.9b USD (calculated: Debt 43.2b - CCE 3.26b)
Enterprise Value = 234b USD (195b + Debt 43.2b - CCE 3.26b)
Interest Coverage Ratio = 5.89 (Ebit TTM 8.66b / Interest Expense TTM 1.47b)
EV/FCF = 34.74x (Enterprise Value 234b / FCF TTM 6.75b)
FCF Yield = 2.88% (FCF TTM 6.75b / Enterprise Value 234b)
FCF Margin = 14.93% (FCF TTM 6.75b / Revenue TTM 45.2b)
Net Margin = 15.18% (Net Income TTM 6.86b / Revenue TTM 45.2b)
Gross Margin = 39.41% ((Revenue TTM 45.2b - Cost of Revenue TTM 27.4b) / Revenue TTM)
Gross Margin QoQ = 40.67% (prev 37.95%)
Tobins Q-Ratio = 2.07 (Enterprise Value 234b / Total Assets 113b)
Interest Expense / Debt = 3.41% (Interest Expense 1.47b / Debt 43.2b)
Taxrate = 7.06% (522.0m / 7.40b)
NOPAT = 8.05b (EBIT 8.66b * (1 - 7.06%))
Current Ratio = 1.53 (Total Current Assets 22.3b / Total Current Liabilities 14.6b)
Debt / Equity = 0.83 (Debt 43.2b / totalStockholderEquity, last quarter 51.9b)
Debt / EBITDA = 3.58 (Net Debt 39.9b / EBITDA 11.2b)
Debt / FCF = 5.91 (Net Debt 39.9b / FCF TTM 6.75b)
Total Stockholder Equity = 51.7b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.46% (Net Income 6.86b / Total Assets 113b)
RoE = 13.26% (Net Income TTM 6.86b / Total Stockholder Equity 51.7b)
RoCE = 9.43% (EBIT 8.66b / Capital Employed (Equity 51.7b + L.T.Debt 40.1b))
RoIC = 8.09% (NOPAT 8.05b / Invested Capital 99.5b)
WACC = 7.40% (E(195b)/V(238b) * Re(8.34%) + D(43.2b)/V(238b) * Rd(3.41%) * (1-Tc(0.07)))
Discount Rate = 8.34% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.01 | Cagr: -1.74%
[DCF] Terminal Value 75.49% ; FCFF base≈6.74b ; Y1≈6.79b ; Y5≈7.23b
[DCF] Fair Price = 195.1 (EV 112b - Net Debt 39.9b = Equity 72.5b / Shares 371.6m; r=8.35% [WACC [floored]]; 5y FCF grow 0.36% → 2.50% )
EPS Correlation: 92.12 | EPS CAGR: 3.23% | SUE: 1.59 | # QB: 3
Revenue Correlation: 58.22 | Revenue CAGR: 1.30% | SUE: 1.40 | # QB: 5
EPS current Quarter (2026-06-30): EPS=5.71 | Chg30d=-0.10% | Revisions=-59% | Analysts=21
EPS next Quarter (2026-09-30): EPS=6.37 | Chg30d=+0.19% | Revisions=+40% | Analysts=21
EPS current Year (2026-12-31): EPS=24.85 | Chg30d=-0.02% | Revisions=+40% | GrowthEPS=+8.7% | GrowthRev=+7.2%
EPS next Year (2027-12-31): EPS=27.26 | Chg30d=-0.03% | Revisions=+17% | GrowthEPS=+9.7% | GrowthRev=+5.4%
[Analyst] Revisions Ratio: -21% (up=8, down=13)